Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm Announces Plans for Reorganization Under Chapter 11 of the U.S. Bankruptcy Code
Feb 15, 2019
HAYWARD, Calif. --(BUSINESS WIRE)--Feb. 15, 2019-- Aradigm Corporation (OTCQB: ARDM) (“Aradigm” or the “Company”) has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the Alameda County Court District to facilitate the sale of its assets.
Aradigm Announces Submission of Responses to EMA Day 120 Questions and Meeting with FDA
Jan 30, 2019
HAYWARD, Calif. --(BUSINESS WIRE)--Jan. 30, 2019-- Aradigm Corporation (OTCQB: ARDM) (“Aradigm” or the “Company”) submitted responses to the European Medicines Agency (EMA) Day 120 questions on 23 January 2019 . The due date for response to the questions was 25 January.
Aradigm Announces Detailed Third Party Evaluation Results for Apulmiq (FDA)/Linhaliq (EMA)
Jan 16, 2019
HAYWARD, Calif. --(BUSINESS WIRE)--Jan. 16, 2019-- Aradigm Corporation (OTCQB: ARDM) ("Aradigm" or the "Company") today announced specific, detailed results of an independent third party evaluation (TPE) of the Phase 3 clinical trial results for Apulmiq.
Aradigm Announces Results of Third Party Verification for Apulmiq (formerly Linhaliq)
Dec 20, 2018
HAYWARD, Calif. --(BUSINESS WIRE)--Dec. 20, 2018-- Aradigm Corporation (Nasdaq: ARDM) (" Aradigm " or the "Company") today announced results of a third party evaluation (TPE) of the Phase 3 clinical trial results for Apulmiq. Aradigm received a Complete Response Letter (CRL) on 26 January 2018 ,
Aradigm Announces Third Quarter 2018 Financial Results
Nov 15, 2018
HAYWARD, Calif. --(BUSINESS WIRE)--Nov. 15, 2018-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2018 . Third Quarter 2018 Financial Results The Company recorded $282,000 in revenue in the third quarter
Aradigm Announces Second Quarter 2018 Financial Results
Aug 14, 2018

HAYWARD, Calif. --(BUSINESS WIRE)--Aug. 14, 2018-- Aradigm Corporation (NASDAQ: ARDM) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2018 . Second Quarter 2018 Financial Results The Company recorded $256,000 in revenue in the second quarter of

Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Directors
Jul 06, 2018

HAYWARD, Calif. --(BUSINESS WIRE)--Jul. 6, 2018-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced the appointment of Dr. Theresa Matkovits to the Board, the Audit Committee of the Board and the Nominating and Corporate Governance Committee of the Board.

Aradigm Announces First Quarter 2018 Financial Results
May 15, 2018

HAYWARD, Calif. --(BUSINESS WIRE)--May 15, 2018-- Aradigm Corporation (NASDAQ: ARDM) (the “Company”) today announced financial results for the first quarter and three months ended March 31, 2018 . First Quarter 2018 Financial Results The Company recorded $1.5 million in revenue in the first quarter

Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission
Apr 05, 2018

HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 5, 2018-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA) for Linhaliq for the treatment of non-cystic fibrosis

Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results
Mar 23, 2018
Subsequent Highlights Cash and cash equivalents of $7.1 million expected to be sufficient to fund operations for Q1 2018; temporary measures implemented to preserve cash resources Focus on European Approval for Linhaliq – Marketing Authorization Application for EU filed Patients and patient
Aradigm Submits Marketing Authorisation Application (MAA) to EMA for EU Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Mar 09, 2018
HAYWARD, Calif. --(BUSINESS WIRE)--Mar. 9, 2018-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced it has submitted its Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis (NCFBE)
Aradigm Receives Complete Response Letter from the FDA for Linhaliq NDA
Jan 29, 2018
HAYWARD, Calif. --(BUSINESS WIRE)--Jan. 29, 2018-- Aradigm Corporation (NASDAQ: ARDM) (the “Company”) today announces that it received a Complete Response Letter (CRL) from the US Food and Drug Administration ( FDA ) regarding its New Drug Application (NDA) for Linhaliq™ as a treatment for
Aradigm Reports Results of FDA Advisory Committee Meeting on Linhaliq
Jan 11, 2018
HAYWARD, Calif. , Jan. 11, 2018 (GLOBE NEWSWIRE) -- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announces that the Antimicrobial Drugs Advisory Committee (ADAC) of the US Food and Drug Administration (FDA) did not recommend approval for Linhaliq™ as a treatment for non-cystic fibrosis
Aradigm Announces FDA Advisory Committee Meeting for Linhaliq
Dec 01, 2017
Meeting Scheduled for January 11, 2018 HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced that a meeting of the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled for January 11, 2018 to review
Aradigm to Host Key Opinion Leader Meeting and Webcast on November 9 in New York City
Nov 07, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq: ARDM) (the "Company") announced today that it will host a Key Opinion Leader (KOL) Breakfast on the topic of Non-Cystic Fibrosis Bronchiectasis (NCFBE) on Thursday, November 9, 2017 from 8:00-9:30 am Eastern Time in New York, NY .
Aradigm Announces Third Quarter 2017 Financial Results
Nov 02, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2017 . The Company recorded $2.7 million in revenue in the third quarter of 2017 compared with $50,000 in revenue in the
Aradigm Regains Compliance with NASDAQ Listing Requirements
Oct 10, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced that it received notice from The NASDAQ Capital Market ("NASDAQ") indicating that the Company has regained compliance under NASDAQ Listing Rule 5550(a)(2) for continued listing on The
Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status
Sep 25, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis
Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26
Sep 22, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced that Aradigm management will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 , at 2:00 p.m. ET .
Aradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients
Sep 15, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced that it will host a Key Opinion Leader (KOL) call on the topic of infection management in non-cystic fibrosis bronchiectasis (NCFBE) patients on Monday, September 18 at 11am Eastern Time .
Displaying 1 - 20 of 240
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2019 Aradigm Corporation. All Rights Reserved.